NZ749586A - Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells - Google Patents
Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cellsInfo
- Publication number
- NZ749586A NZ749586A NZ749586A NZ74958617A NZ749586A NZ 749586 A NZ749586 A NZ 749586A NZ 749586 A NZ749586 A NZ 749586A NZ 74958617 A NZ74958617 A NZ 74958617A NZ 749586 A NZ749586 A NZ 749586A
- Authority
- NZ
- New Zealand
- Prior art keywords
- vector
- expression
- cancer
- cells
- activating ligand
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662350095P | 2016-06-14 | 2016-06-14 | |
| PCT/US2017/037531 WO2017218689A1 (en) | 2016-06-14 | 2017-06-14 | Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ749586A true NZ749586A (en) | 2023-06-30 |
Family
ID=60664263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ749586A NZ749586A (en) | 2016-06-14 | 2017-06-14 | Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11427625B2 (enExample) |
| EP (1) | EP3468588A4 (enExample) |
| JP (1) | JP7184337B2 (enExample) |
| CN (1) | CN109475613B (enExample) |
| AU (1) | AU2017285213B2 (enExample) |
| CA (1) | CA3027857C (enExample) |
| MX (1) | MX2018015542A (enExample) |
| NZ (1) | NZ749586A (enExample) |
| WO (1) | WO2017218689A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2771110C2 (ru) | 2017-07-26 | 2022-04-26 | Онкорус, Инк. | Онколитические вирусные векторы и их применение |
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS |
| EP3833765B1 (en) * | 2017-08-09 | 2026-01-14 | Ohio State Innovation Foundation | Oncolytic virus carrying e-cadherin and uses thereof |
| EP3781188A4 (en) * | 2018-04-13 | 2022-03-02 | 2seventy bio, Inc. | ADOPTIVE CELL THERAPY |
| WO2020091958A1 (en) * | 2018-11-01 | 2020-05-07 | Onconetics Pharmaceuticals, Inc. | Multi-component vector systems, methods of making, and uses thereof |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CN114980920A (zh) | 2019-11-18 | 2022-08-30 | 詹森生物科技公司 | 基于突变体calr和jak2的疫苗及其用途 |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| JP7724010B2 (ja) * | 2021-04-08 | 2025-08-15 | イムビラ・バイオファーマシューティカルズ・カンパニー・リミテッド | ケモカイン及び腫瘍関連／特異的抗原を送達する遺伝子改変腫瘍溶解性単純ヘルペスウイルス |
| WO2025245495A1 (en) * | 2024-05-24 | 2025-11-27 | Cz Biohub Sf, Llc | Selective sensitization of cancer cells to elimination by cytotoxic lymphocytes |
| CN118389408B (zh) * | 2024-06-26 | 2024-11-29 | 淇嘉科技(苏州)有限公司 | 炎症性肠病及纤维化体外精准模拟方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69831754T2 (de) | 1997-12-17 | 2006-06-29 | Immunex Corp., Thousand Oaks | Zelloberflächenglycoproteinen zusammenhang mit menschlicher b zell lymphomen - ulbp, dns und polypeptiden |
| ATE434624T1 (de) | 2001-10-04 | 2009-07-15 | Immunex Corp | Ul16-bindungsprotein 4 |
| US20150165065A1 (en) * | 2009-12-31 | 2015-06-18 | Avidbiotics Corp. | Non-natural mic proteins |
| WO2012006181A2 (en) * | 2010-06-29 | 2012-01-12 | Mount Sinai School Of Medicine | Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer |
| US20130156808A1 (en) * | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
| KR102490462B1 (ko) | 2013-10-28 | 2023-01-19 | 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 종양분해성 hsv 벡터 |
-
2017
- 2017-06-14 WO PCT/US2017/037531 patent/WO2017218689A1/en not_active Ceased
- 2017-06-14 NZ NZ749586A patent/NZ749586A/en unknown
- 2017-06-14 AU AU2017285213A patent/AU2017285213B2/en active Active
- 2017-06-14 CA CA3027857A patent/CA3027857C/en active Active
- 2017-06-14 JP JP2018566257A patent/JP7184337B2/ja active Active
- 2017-06-14 MX MX2018015542A patent/MX2018015542A/es unknown
- 2017-06-14 US US16/309,862 patent/US11427625B2/en active Active
- 2017-06-14 EP EP17814031.5A patent/EP3468588A4/en active Pending
- 2017-06-14 CN CN201780036512.5A patent/CN109475613B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017218689A9 (en) | 2018-12-13 |
| AU2017285213A1 (en) | 2019-01-17 |
| US11427625B2 (en) | 2022-08-30 |
| CA3027857A1 (en) | 2017-12-21 |
| CA3027857C (en) | 2023-07-25 |
| AU2017285213B2 (en) | 2024-05-16 |
| CN109475613A (zh) | 2019-03-15 |
| EP3468588A4 (en) | 2019-12-11 |
| EP3468588A1 (en) | 2019-04-17 |
| WO2017218689A1 (en) | 2017-12-21 |
| JP7184337B2 (ja) | 2022-12-06 |
| JP2019517815A (ja) | 2019-06-27 |
| CN109475613B (zh) | 2024-02-20 |
| US20200148742A1 (en) | 2020-05-14 |
| MX2018015542A (es) | 2019-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018015542A (es) | Expresion de proteinas de ligando activadoras de nkg2d para la sensibilizacion de celulas cancerosas para el ataque por celulas inmunocitotoxicas. | |
| Davola et al. | Oncolytic viruses: how “lytic” must they be for therapeutic efficacy? | |
| Jaworski et al. | Human T-lymphotropic virus type 1-infected cells secrete exosomes that contain Tax protein | |
| EP4141111A4 (en) | ONCOLYTIC VIRUS VACCINE AND DRUG FOR THE TREATMENT OF TUMORS BY COMBINATION OF ONCOLYTIC VIRUS VACCINE WITH IMMUNE CELLS | |
| AU2016256582A8 (en) | Oncolytic adenovirus encoding a B7 protein | |
| PH12018501291A1 (en) | Group b adenovirus encoding an anti-tcr-complex antibody or fragment | |
| MX2021001883A (es) | Virus recombinantes del mixoma y usos de los mismos. | |
| MX2017008173A (es) | Terapias de combinacion con cepas de listeria recombinantes. | |
| WO2016073955A3 (en) | Cells lacking b2m surface expression and methods for allogeneic administration of such cells | |
| EP4403635A3 (en) | Fusion protein comprising il-2 protein and cd80 protein, and use thereof | |
| MX2018009126A (es) | Vectores virales oncoliticos y usos de estos. | |
| EP4257675A3 (en) | Delivery of materials to anucleate cells | |
| NZ616304A (en) | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| WO2016073595A8 (en) | T cells and dendritic cells for polyomavirus therapy | |
| MX363819B (es) | Uniones a cdim y sus usos. | |
| WO2021011936A3 (en) | Cell-type selective immunoprotection of cells | |
| MX2024004610A (es) | Receptores de celulas t restringidas a hla de clase ii contra ras mutado. | |
| AR110632A1 (es) | Vectores del adenovirus canino | |
| MX2023009084A (es) | Anticuerpos anti-virus del dengue, polipeptidos que contienen regiones fc variantes y metodos de uso. | |
| MX2015003717A (es) | Polipeptidos del virus de chikungunya que expresan el virus de sarampion recombinante y sus aplicaciones. | |
| BR112019024656A2 (pt) | vírus oncolíticos para a sensibilização de células tumorais para morte por células exterminadoras naturais | |
| MX2022005670A (es) | Composiciones y metodos para recombinacion de alta eficiencia de moleculas de arn. | |
| AU2017256910A1 (en) | Optogenetic visual restoration using Chrimson | |
| MY184126A (en) | Transposon system, kit comprising the same, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240502 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JUN 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250501 |